VEGFC and Alzheimer disease: As mentioned earlier, adult AD mice (5-6 months old) are not afflicted by meningeal lymphatic impairments until they get older (> 13 months old) [75], which might explain why VEGF-C adenoviral therapy had no observable effect in the AD animal models using adult mice.